STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	1	Manuscript title
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	3	Line 30-51
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4	Line 54-69
Objectives	3	State specific objectives, including any prespecified hypotheses	4	Line 70-71
Methods				
Study design	4	Present key elements of study design early in the paper	5	Line 76-77
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6	Line 101-106
Participants	6	(*a*) *Cohort study*—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up *Case-control study*—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls *Cross-sectional study*—Give the eligibility criteria, and the sources and methods of selection of participants	6	Line 107-114 Figure 1 (Flowchart)
		(*b*) *Cohort study*—For matched studies, give matching criteria and number of exposed and unexposed *Case-control study*—For matched studies, give matching criteria and the number of controls per case	N/A	N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7	Line 129-136
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7	Line 120-126
Bias	9	Describe any efforts to address potential sources of bias	6	Line 103-104
Study size	10	Explain how the study size was arrived at	6	Line 101-102

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	N/A	
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	7	Line 140-146
		(*b*) Describe any methods used to examine subgroups and interactions	7	Line 142-143
		(*c*) Explain how missing data were addressed	N/A	
		(*d*) *Cohort study*—If applicable, explain how loss to follow-up was addressed *Case-control study*—If applicable, explain how matching of cases and controls was addressed *Cross-sectional study*—If applicable, describe analytical methods taking account of sampling strategy		
		(*e*) Describe any sensitivity analyses	N/A	
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	21	Figure 1 (Flowchart)
		(b) Give reasons for non-participation at each stage	21	Figure 1 (Flowchart)
		(c) Consider use of a flow diagram	21	Figure 1 (Flowchart)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9	Line 172-177
		(b) Indicate number of participants with missing data for each variable of interest	14	Table 1
		(c) *Cohort study*—Summarise follow-up time (eg, average and total amount)	9	Line 177-178
Outcome data	15*	*Cohort study*—Report numbers of outcome events or summary measures over time	10	Line 200
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	N/A	
		Cross-sectional study—Report numbers of outcome events or summary measures	N/A	
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10	Line 190-215
		(*b*) Report category boundaries when continuous variables were categorized	N/A	
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A	

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A	
Discussion				
Key results	18	Summarise key results with reference to study objectives	11	Line 218-221
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12	Line 250-260
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12	Line 242-249
Generalisability	21	Discuss the generalisability (external validity) of the study results	12	Line 223-249
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	8	Line 162-165

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.